Literature DB >> 284840

Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood.

J S Lobel, R T O'Brien, S McIntosh, G T Aspnes, R L Capizzi.   

Abstract

Two groups of children with refractory acute lymphoblastic leukemia were treated with a regimen of methotrexate (MTX) and asparaginase (Asn'ase) based on studies of the effect of MTX in vitro on human lymphoblasts exposed to Asn'ase. Induction therapy in 12 children produced 4 complete remissions, 3 partial remissions, and 5 failures. Responsiveness to Asn'ase seemed necessary for successful induction with the drug combinations. Maintenance therapy in 18 children produced a median hematologic remission of 31 weeks (range 3-85 weeks). During remission, 2 children developed central nervous system leukemia and 2 died of infection. The mean maximally tolerated dose of MTX was 361 mg/m2. The results of this trial suggest therapeutic synergy in maintenance therapy and the capability of Asn'ase to attenuate MTX toxicity.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 284840     DOI： 10.1002/1097-0142(197903)43:3<1089::aid-cncr2820430346>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  7 in total

1.  Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Tapan M Kadia; Hagop M Kantarjian; Deborah A Thomas; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Naveen Pemmaraju; Naval Daver; Xuemei Wang; Preetesh Jain; Sherry Pierce; Mark Brandt; Guillermo Garcia-Manero; Jorge Cortes; Gautam Borthakur
Journal:  Am J Hematol       Date:  2014-11-19       Impact factor: 10.047

Review 2.  Asparagine synthetase chemotherapy.

Authors:  Nigel G J Richards; Michael S Kilberg
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

Review 3.  Challenges and opportunities in childhood cancer drug development.

Authors:  Robin E Norris; Peter C Adamson
Journal:  Nat Rev Cancer       Date:  2012-10-11       Impact factor: 60.716

4.  Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.

Authors:  Peter G Steinherz; Nita L Seibel; Harland Sather; Lingyun Ji; Xinxin Xu; Meenakshi Devidas; Paul S Gaynon
Journal:  Leukemia       Date:  2019-02-28       Impact factor: 11.528

5.  Therapy of acute lymphocytic leukemia in childhood with intermediate dose methotrexate and CNS irradiation. A report of the ALL 77-02 study group.

Authors:  R J Haas; G Janka; G Gaedicke; E Kohne; B Netzel
Journal:  Blut       Date:  1983-12

Review 6.  Folate metabolism: a re-emerging therapeutic target in haematological cancers.

Authors:  Martha M Zarou; Alexei Vazquez; G Vignir Helgason
Journal:  Leukemia       Date:  2021-03-11       Impact factor: 11.528

7.  Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort Study.

Authors:  Solenne Le Louet; Véronique Icart; Marion Strullu; Arnaud Petit; Claire Freycon; Pascale Blouin; Jill Serre; Nicolas Rama; Yves Reguerre; Christophe Piguet; Marlène Pasquet; Audrey David; Pauline Simon; Marilyne Poiree; Liana Carausu; Fanny Rialland; Wadih Abouchahla; Paul Saultier; Stéphane Ducassou; Julie Valduga; André Baruchel; Yves Bertrand; Carine Domenech
Journal:  J Cancer       Date:  2022-01-24       Impact factor: 4.207
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.